These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 2479327

  • 1. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M, Modan M, Rusoshansky S, Bairey O, Shaklai M.
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [Abstract] [Full Text] [Related]

  • 2. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M, Li L, Qiu M, Yan X, Zhu J, Gou HF.
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [Abstract] [Full Text] [Related]

  • 3. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas].
    Pieresca C, Gobbi PG, Bertoloni D, Grignani G, Rossi A, Legnani MC, Giordano M.
    Ann Ital Med Int; 1991 Apr; 6(3):267-72. PubMed ID: 1723289
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G, Bigazzi C, Bocchia M, Forconi F, Lauria F.
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [Abstract] [Full Text] [Related]

  • 5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    N Engl J Med; 1993 Apr 08; 328(14):1002-6. PubMed ID: 7680764
    [Abstract] [Full Text] [Related]

  • 6. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 08; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI.
    Semin Hematol; 1988 Apr 08; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [Abstract] [Full Text] [Related]

  • 9. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
    Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M.
    Int J Oncol; 2000 Jan 08; 16(1):149-54. PubMed ID: 10601560
    [Abstract] [Full Text] [Related]

  • 10. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD, Wolff SN, Stein RS, Greer JP, Cousar JB, Greco FA.
    Cancer Treat Rep; 1986 Aug 08; 70(8):953-8. PubMed ID: 3015406
    [Abstract] [Full Text] [Related]

  • 11. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI.
    J Clin Oncol; 1991 Jan 08; 9(1):25-38. PubMed ID: 1702144
    [Abstract] [Full Text] [Related]

  • 12. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI.
    J Clin Oncol; 1990 Dec 08; 8(12):1951-8. PubMed ID: 1700079
    [Abstract] [Full Text] [Related]

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 08; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 14. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC.
    J Clin Oncol; 1994 Oct 08; 12(10):2153-9. PubMed ID: 7523607
    [Abstract] [Full Text] [Related]

  • 15. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Wang A, Luo Y, Wang Z.
    Zhonghua Zhong Liu Za Zhi; 1997 May 08; 19(3):215-7. PubMed ID: 10920901
    [Abstract] [Full Text] [Related]

  • 16. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
    Montserrat E, García-Conde J, Viñolas N, López-Guillermo A, Hernández-Nieto L, Zubizarreta A, Maldonado J, Alcalá A, Faura MV, Llorente A, Bladé J, Fontanillas M, Estapé J.
    Eur J Haematol; 1996 Nov 08; 57(5):377-83. PubMed ID: 9003479
    [Abstract] [Full Text] [Related]

  • 17. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR.
    Cancer Treat Rep; 1982 Jun 08; 66(6):1279-84. PubMed ID: 6177407
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 08; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 19. ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
    Fisher RI, Young RC, Longo D, DeVita VT.
    Semin Oncol; 1985 Mar 08; 12(1 Suppl 2):29-32. PubMed ID: 2579441
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC.
    Ann Oncol; 1991 Jan 08; 2 Suppl 1():33-5. PubMed ID: 1710487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.